EuPFI 2019 Poster: Development of a Paediatric Oral Suspension of a Novel Drug for the Treatment of Kidney Disease
10 September 2019
Overview
This development program aimed to develop an aqueous,multi-dose oral suspension formulation of a novel drug candidate at a concentration of 20mg/ml that would be appropriate for the treatment of kidney disease in pediatric patients aged 2 years and older. A liquid formulation was favored over a coated granule formulation.
Download Quotient Sciences' poster, 'EuPFI 2019 Poster-Development of a Paediatric Oral Suspension of a Novel Drug for the Treatment of Kidney Disease'.